tiprankstipranks
Advertisement
Advertisement

TIL Stock Latest News

Instil Bio Shareholders Back Directors and Auditor at Meeting
Company AnnouncementsInstil Bio Shareholders Back Directors and Auditor at Meeting
17d ago
8K
TIL
Instil Bio Faces Heightened Cybersecurity Threats as Data Breach Risks Jeopardize Clinical Trials and Long-Term Strategy
PremiumCompany Announcements
Instil Bio Faces Heightened Cybersecurity Threats as Data Breach Risks Jeopardize Clinical Trials and Long-Term Strategy
3M ago
TIL
Instil Bio, Inc. (TIL) Q4 Earnings Cheat Sheet
PremiumPre-Earnings
Instil Bio, Inc. (TIL) Q4 Earnings Cheat Sheet
4M ago
TIL
Instil Bio downgraded to Neutral from Buy at H.C. Wainwright
PremiumThe Fly
Instil Bio downgraded to Neutral from Buy at H.C. Wainwright
6M ago
TIL
Instil Bio Ends Key Oncology Licensing Agreement with ImmuneOnco
PremiumCompany Announcements
Instil Bio Ends Key Oncology Licensing Agreement with ImmuneOnco
6M ago
8K
TIL
Baird downgrades Instil Bio on discontinuation of AXN-2510
PremiumThe FlyBaird downgrades Instil Bio on discontinuation of AXN-2510
6M ago
TIL
Instil Bio downgraded to Neutral from Outperform at Baird
Premium
The Fly
Instil Bio downgraded to Neutral from Outperform at Baird
6M ago
TIL
Instil Bio’s Axion discontinues clinical development of AXN-2510
Premium
The Fly
Instil Bio’s Axion discontinues clinical development of AXN-2510
6M ago
TIL
Instil Bio reports Q3 EPS ($1.75) vs ($2.55) last year
PremiumThe Fly
Instil Bio reports Q3 EPS ($1.75) vs ($2.55) last year
8M ago
TIL
Instil Bio’s AXN-2510 Study: A Promising Step in Cancer Treatment
PremiumCompany Announcements
Instil Bio’s AXN-2510 Study: A Promising Step in Cancer Treatment
8M ago
TIL
Citizens JMP healthcare analysts hold an analyst/industry conference call
PremiumThe Fly
Citizens JMP healthcare analysts hold an analyst/industry conference call
9M ago
TIL
CBIO
Instil Bio’s AXN-2510: Promising Data and Valuation Gap Justify Buy Rating
PremiumRatings
Instil Bio’s AXN-2510: Promising Data and Valuation Gap Justify Buy Rating
10M ago
TIL
Instil Bio announces ImmuneOnco presentation of ‘2510 monotherapy data
PremiumThe FlyInstil Bio announces ImmuneOnco presentation of ‘2510 monotherapy data
10M ago
TIL
Instil Bio’s Promising Outlook: Buy Rating Supported by Successful Trials and Market Potential
Premium
Ratings
Instil Bio’s Promising Outlook: Buy Rating Supported by Successful Trials and Market Potential
10M ago
TIL
Instil Bio Receives Buy Rating Amid Promising Trial Data and Strong Financial Outlook
Premium
Ratings
Instil Bio Receives Buy Rating Amid Promising Trial Data and Strong Financial Outlook
11M ago
TIL
Instil Bio Reports Promising Phase 2 Study Results
PremiumCompany Announcements
Instil Bio Reports Promising Phase 2 Study Results
11M ago
8K
TIL
Instil Bio: ImmuneOnco reports results from Phase 2 study of IMM2510/AXN-2510
PremiumThe Fly
Instil Bio: ImmuneOnco reports results from Phase 2 study of IMM2510/AXN-2510
11M ago
TIL
Instil Bio announces FDA clearance of IND application for AXN-2510
PremiumThe Fly
Instil Bio announces FDA clearance of IND application for AXN-2510
12M ago
TIL
Instil Bio adds Maraganore to the Board of Directors of Axion Bio
PremiumThe Fly
Instil Bio adds Maraganore to the Board of Directors of Axion Bio
1y ago
TIL
Instil Bio Positioned as a Promising Player in the PD-1/L1 x VEGF Market with Strong Buy Recommendation
PremiumRatingsInstil Bio Positioned as a Promising Player in the PD-1/L1 x VEGF Market with Strong Buy Recommendation
1y ago
TIL
Instil Bio appoints Jamie Freedman as CMO
Premium
The Fly
Instil Bio appoints Jamie Freedman as CMO
1y ago
TIL
Instil Bio Elects Director and Ratifies Auditor
Premium
Company Announcements
Instil Bio Elects Director and Ratifies Auditor
1y ago
8K
TIL

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >